ISSN 0269-8811; 1461-7285;
33 papers in the library · 4,078 citations · publishing 2008-2026
J Psychopharmacol August 5, 2026
CB1 receptor-enriched functional connectivity analysis revealed target-specific modulation by cannabidiol in early psychosis.
J Psychopharmacol August 3, 2026
Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models.
J Psychopharmacol June 28, 2026 Yingjie Du, Xiangting Zhao, Yishan Yao et al.
BACKGROUND: Posttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by...
J Psychopharmacol February 27, 2026
Prenatal THC exposure and binge-like alcohol drinking in early adolescence: From sex-specific drinking vulnerability to abnormal endocannabinoid-dopamine nexus in the nucleus accumbens.
J Psychopharmacol October 27, 2025 David Nutt, Celia J. A. Morgan, David Erritzøe et al. 2 citations
A long, strange trip: Ketamine treatment in psychiatry.
J Psychopharmacol October 22, 2025 correction
Corrigendum to: Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.
J Psychopharmacol October 29, 2024 Otto Simonsson, Simon B. Goldberg, Peter S. Hendricks 4 citations
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
J Psychopharmacol July 29, 2024 Claire Walker, Timothy Piatkowski, Jason Ferris et al. 4 citations
INTRODUCTION: This study explores how individuals self-treat psychiatric conditions with psychedelics outside medical guidance bridging the gap in understanding unregulated therapeutic use. AIMS: The primary objective was to extract specific factors underlying the effects of psychedelics, exploring their relationship with the need for medication, particularly for mental health conditions like...
J Psychopharmacol April 23, 2024 Evan Cole Lewis, Alexandria Jaeger, Manesh Girn et al. 6 citations
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.
J Psychopharmacol March 4, 2024 Alessia Marrocu, Hannes Kettner, Brandon Weiss et al. 51 citations
Background: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited...
J Psychopharmacol January 27, 2024 Jessica Barbut Siva, Tommaso Barba, Hannes Kettner et al. 29 citations
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.
J Psychopharmacol June 30, 2023 Chloé Pronovost-Morgan, Ido Hartogsohn, Johannes G. Ramaekers 33 citations
The randomized controlled trial (RCT) research design assumes that a drug's "specific" effect can be isolated, added, and subtracted from the "nonspecific" effect of context and person. While RCTs are helpful in assessing the added benefit of a novel drug, they tend to obscure the curative potential of extra-pharmacological variables, known as "the placebo effect." Ample empirical evidence...
J Psychopharmacol February 28, 2023 Polina Ponomarenko, Federico Seragnoli, Abigail E. Calder et al. 22 citations
BACKGROUND: Despite the growth of psychedelic research, psychedelic-assisted group psychotherapy (PAGP) has received little attention in comparison to individual psychedelic-assisted psychotherapy models. METHODS: In this article, we aim to discuss the therapeutic potential of PAGP, as well as outline existing models and the challenges of this approach. Using Irvin Yalom's 11 therapeutic...
J Psychopharmacol December 17, 2022 Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues 57 citations
Ketamine is an N-methyl-d-aspartate antagonist which is increasingly being researched and used as a treatment for depression. In low doses, it can cause a transitory modification in consciousness which was classically labelled as ‘dissociation’. However, ketamine is also commonly classified as an atypical psychedelic and it has been recently reported that ego dissolution experiences during...
J Psychopharmacol August 1, 2022 Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen et al. 73 citations
Background: Over the last two decades, a number of studies have highlighted the potential of psychedelic therapy. However, questions remain to what extend these results translate to naturalistic samples, and how contextual factors and the acute psychedelic experience relate to improvements in affective symptoms following psychedelic experiences outside labs/clinics. The present study sought to...
J Psychopharmacol February 2, 2022 Anne K. Schlag, Jacob S. Aday, Iram Salam et al. 319 citations
BACKGROUND: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. OBJECTIVE: This narrative review examines the evidence for potential harms of the classic psychedelics by separating...
J Psychopharmacol January 5, 2022 Joseph Peill, Katie Trinci, Hannes Kettner et al. 135 citations
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
J Psychopharmacol December 13, 2021 Ben Sessa, Jacob S. Aday, Steve O’Brien et al. 18 citations
BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although...
J Psychopharmacol July 5, 2021
More than just smoke: Psychopharmacology of cannabinoids.
J Psychopharmacol April 22, 2021 Robin Carhart-Harris, Anne C Wagner, Manish Agrawal et al. 54 citations
Favourable regulatory assessments, liberal policy changes, new research centres and substantial commercial investment signal that psychedelic therapy is making a major comeback. Positive findings from modern trials are catalysing developments, but it is questionable whether current confirmatory trials are sufficient for advancing our understanding of safety and best practice. Here we suggest...
J Psychopharmacol February 18, 2021 Ben Sessa, Laurie Higbed, Steve O’Brien et al. 123 citations
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.
J Psychopharmacol February 10, 2021 Carla Pallavicini, Federico Cavanna, Federico Zamberlán et al. 73 citations
BACKGROUND: N,N-dimethyltryptamine is a short-acting psychedelic tryptamine found naturally in many plants and animals. Few studies to date have addressed the neural and psychological effects of N,N-dimethyltryptamine alone, either administered intravenously or inhaled in freebase form, and none have been conducted in natural settings. AIMS: Our primary aim was to study the acute effects of...
J Psychopharmacol June 15, 2020 Anna Borissova, Bart Ferguson, Matthew B. Wall et al. 37 citations
BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA) is being actively researched as an adjunct to psychotherapy. It may be beneficial to trust, empathy and cooperative behaviour due to its acute prosocial effects. AIM: To test (a) the acute effects of MDMA on measures of empathy, trust and cooperative behaviour, and (b) subacute changes in mood three days after MDMA administration. METHODS: =7...
J Psychopharmacol July 11, 2019 Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato et al. 415 citations
Background: Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough....
J Psychopharmacol February 28, 2019 David Erritzøe, James Smith, Patrick M. Fisher et al. 95 citations
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.